PX-478, an HIF-1α inhibitor, impairs mesoCAR T cell antitumor function in cervical cancer.

ABSTRACT:

Introduction

Chimeric Antigen Receptor (CAR) T cell therapy has demonstrated remarkable success in treating hematological malignancies. However, its efficacy against solid tumors, including cervical cancer, remains a challenge. Hypoxia, a common feature of the tumor microenvironment, profoundly impacts CAR T cell function, emphasizing the need to explore strategies targeting hypoxia-inducible factor-1α (HIF-1α).

Methods

In this study, we evaluated the effects of the HIF-1α inhibitor PX-478 on mesoCAR T cell function through in-silico and in vitro experiments. We conducted comprehensive analyses of HIF-1α expression in cervical cancer patients and examined the impact of PX-478 on T cell proliferation, cytokine production, cytotoxicity, and exhaustion markers.

Result

SUBMITTER: Panahi Meymandi AR 

PROVIDER: S-EPMC10903365 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature